Roche’s Actemra Beat Abbott Drug in Rheumatoid Arthritis

Roche Holding AG’s rheumatoid arthritis drug Actemra beat Humira from Abbott Laboratories in a test that Roche said may widen use of its therapy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.